Navigation Links
Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'
Date:10/20/2008

NEW BRUNSWICK, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting her findings related to Senesco's preclinical multiple myeloma data at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics." Ms. Taylor is a member of the Department of Biology at the University of Waterloo, Ontario, Canada. The conference will take place from October 21-24 in Geneva, Switzerland.

Senesco's President and CEO, Bruce Galton, Executive Vice President and CSO, Dr. John E. Thompson, and Vice President of R&D, Richard Dondero, are all co-authors of the study entitled "Therapeutic intervention in a murine model of multiple myeloma with PEI nanocomplexes bearing an eIF5A siRNA and eIF5AK50R pDNA resulted in a significant anti-tumoural response."

A copy of the poster will be available at http://www.senesco.com once the presentation has been made.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contacts: Investor Relations Contact:

Senesco Technologies, Inc. FD

Bruce Galton Brian Ritchie

Chief Executive Officer (brian.ritchie@fd.com)

(bgalton@senesco.com) (212) 850-5600

(732) 296-8400


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab Announces Encouraging Preclinical Data for ofatumumab
2. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
3. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
4. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
5. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
11. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? ... partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 years ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
(Date:3/22/2017)... 22, 2017 /PRNewswire/ - FACIT announced a seed ... "Propellon"), a start-up created by FACIT focused on ... investment, combined with non-dilutive capital, achieves a targeted ... funding enables Propellon to accelerate the nomination of ... financing and/or entering a strategic partnership for clinical ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical ... desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is ... antibodies. , To meet this demand, the team at SCIEX has developed ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
Breaking Biology News(10 mins):